Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab + Zanubrutinib in Hairy Cell Leukemia (RiZan)
NCT07690761Phase 2Enrolling by invitation
- Sponsor
- Bnai Zion Medical Center
- Start
- Jun 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib in hairy cell leukemia (HCL), Hairy cell leukemia variant (HCL-V), sponsored by Bnai Zion Medical Center. Started Jun 2026; status: enrolling by invitation.
02
Drugs
zanubrutinib
03
Conditions
hairy cell leukemia (HCL)Hairy cell leukemia variant (HCL-V)
Beyond the preview
Go deeper on NCT07690761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07690761.